Replies to post #85587 on PharmaCyte Biotech Inc (PMCB)

[concordia]

Here is an example of the many lies Shady Kenny has told. How many more would you like.

SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of Production Cell Banks. These cell banks are necessary steps in the production of the cells to be encapsulated using the Cell-in-a-Box(R) technology for PharmaCyte Biotech’s Phase 2b clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.

“ViruSure has previous experience in handling the exact cell line that will be used in our Phase 2b clinical trials, which was a major factor in PharmaCyte Biotech selecting ViruSure for this important step in our preparations for these trials,” said Kenneth L. Waggoner, CEO and President of PharmaCyte Biotech. “This decision was further supported by our on-site inspection of the ViruSure facilities and the excellent historical relationships between ViruSure’s key personnel with our partners at Austrianova. ViruSure has years of experience in producing and maintaining cell banks and is an industry leader in this arena.”

“We are delighted to be partnering with PharmaCyte Biotech on such an important project and in helping to bring this much needed therapy for such a devastating disease as pancreatic cancer to the clinic,” stated Andy Bailey, CEO and co-founder of ViruSure.

The cells that will make up the Master, Working and End of Production Cell Banks will be those that convert the anticancer drug ifosfamide into its cancer-killing form. These therapeutic cells will be shipped to ViruSure for propagation. First a Master Cell Bank will be established where aliquots of cells will be stored frozen. Cells from the Master Cell Bank will be propagated to make up the large number of cells that will comprise the Working Cell Bank. Ultimately, cells from the Working Cell Bank will be encapsulated using the Cell-in-a-Box(R) live cell encapsulation technology. An End of Production Cell Bank will then be made from the final product for quality control purposes. The encapsulated cell product, together with ifosfamide, forms PharmaCyte Biotech’s treatment for pancreatic cancer.